1. Home
  2. PROF vs IKT Comparison

PROF vs IKT Comparison

Compare PROF & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$6.80

Market Cap

247.5M

Sector

Health Care

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.02

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROF
IKT
Founded
N/A
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.5M
220.5M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
PROF
IKT
Price
$6.80
$2.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$12.00
$5.00
AVG Volume (30 Days)
75.8K
1.1M
Earning Date
05-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
25.89
57.76
EPS
0.19
N/A
Revenue
$16,098,000.00
N/A
Revenue This Year
$92.40
N/A
Revenue Next Year
$64.10
N/A
P/E Ratio
$36.63
N/A
Revenue Growth
50.73
N/A
52 Week Low
$3.92
$1.33
52 Week High
$8.95
$2.36

Technical Indicators

Market Signals
Indicator
PROF
IKT
Relative Strength Index (RSI) 47.19 59.34
Support Level $6.43 $1.63
Resistance Level $7.06 $2.16
Average True Range (ATR) 0.38 0.14
MACD -0.01 0.00
Stochastic Oscillator 31.75 35.24

Price Performance

Historical Comparison
PROF
IKT

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: